All In Biotech

Drug Trial Radar · NCT07650227

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients

Multicenter, Double Blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 308 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

308

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Materia Medica HoldingIndustry
Sponsor type
Industry
First posted
Jun 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Raphamin works to treat acute bronchitis in adults. It will also learn about the efficacy and the safety of Raphamin. The main questions it aims to answer are: Will treatment with Rafamine contribute to a faster resolution of acute bronchitis symptoms, reduce the severity of the disease, and prevent the development of complications requiring antibacterial therapy compared to placebo therapy? Investigators will compare Raphamin to a placebo (a look-alike substance that contains no drug) to see if Raphamin works to treat acute bronchitis. Participants will: Take Raphamin or a placebo for 5 days. On the first day of treatment 8 tablets of Raphamin or a placebo should be taken using the following regimen: 1 tablet every 30 minutes for the first 2 hours (5 tablets in total for 2 hours), then 1 more tablet 3 times at equal intervals during the same day. On day 2 and onwards, 1 tablet should be taken 3 times a day. Face-to-face visits are planned in the trial: Visit 1 (Day 1), Visit 2 (Day 4±1), Visit 3 (Day 7±1), and a phone Visit 4 (day 14±1). The study uses an electronic patient diary (EPD) in which symptoms of acute bronchitis (cough, sputum, chest pain during coughing) are assessed daily.

Conditions

  • Bronchitis
  • Acute Bronchitis

Interventions

  • RaphaminDrug

    Oral administration

  • PlaceboDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with the Bronchitis Severity Scale, (BSS) score of 4 points or lessTime frame: On day 4

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Aramil City Hospital

    Aramil, Russia · Recruiting

  • Gatchina Clinical Interdistrict Hospital

    Gatchina, Russia · Recruiting

  • City Clinical Hospital No # 9 of the Ministry of Health of the Udmurt Republic

    Izhevsk, Russia · Not yet recruiting

  • Kazan State Medical University/Department of Infectious Diseases

    Kazan', Russia · Recruiting

  • Kazan State Medical University/Department of Internal Medicine

    Kazan', Russia · Recruiting

  • Main Military Clinical Hospital named after Academician N.N. Burdenko/Therapeutic department

    Moscow, Russia · Not yet recruiting

  • First Moscow State Medical University named after I.M. Sechenov/University Clinical Hospital # 4

    Moscow, Russia · Not yet recruiting

  • LLC "Persona Group of Companies"

    Nizhny Novgorod, Russia · Recruiting

  • LLC "Professorial Clinic"

    Perm, Russia · Recruiting

  • LLC "Ultrasound clinic 4D"

    Pyatigorsk, Russia · Recruiting

  • Rostov Central District Hospital

    Rostov-on-Don, Russia · Recruiting

  • St. Petersburg Research Institute of Phthisiopulmonology

    Saint Petersburg, Russia · Recruiting

  • City Polyclinic # 44

    Saint Petersburg, Russia · Recruiting

  • LLC "Energy of Health"

    Saint Petersburg, Russia · Recruiting

  • LLC "Medical Center "Reavita Med St. Petersburg"

    Saint Petersburg, Russia · Recruiting

  • LLC "Medical Clinic"

    Saint Petersburg, Russia · Recruiting

  • City Polyclinic # 112

    Saint Petersburg, Russia · Recruiting

  • LLC "Starry Clinic"

    Saint Petersburg, Russia · Recruiting

  • LLC "YAKUSI Clinic"

    Saint Petersburg, Russia · Recruiting

  • City Polyclinic # 34

    Saint Petersburg, Russia · Recruiting

  • Institute of Experimental Medicine

    Saint Petersburg, Russia · Not yet recruiting

  • Pokrovskaya City Hospital

    Saint Petersburg, Russia · Recruiting

  • City Polyclinic # 3

    Saint Petersburg, Russia · Recruiting

  • City Polyclinic # 4

    Saint Petersburg, Russia · Recruiting

  • LLC "Meili"

    Saint Petersburg, Russia · Recruiting

  • Samara City Hospital # 4

    Samara, Russia · Recruiting

  • Samara State Medical University/Department of Infectious Diseases with Epidemiology

    Samara, Russia · Recruiting

  • Saratov State Medical University named after V.I. Razumovsky/Department of Faculty Therapy

    Saratov, Russia · Recruiting

  • Smolensk State Medical University/Medical and Consultative Center "Academy of Health"

    Smolensk, Russia · Recruiting

  • Scientific Medical Center of General Therapy and Pharmacology

    Stavropol, Russia · Recruiting

  • Ulyanovsk Regional Clinical Hospital

    Ulyanovsk, Russia · Recruiting

  • Voronezh Regional Clinical Hospital # 1/Pulmonology department

    Voronezh, Russia · Recruiting

  • LLC "Medical Center for Diagnostics and Prevention Plus"

    Yaroslavl, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.